90 related articles for article (PubMed ID: 14709967)
1. More data for the CYP2D6 hypothesis?: the in vivo inhibition of CYP2D6 isoenzyme and extrapyramidal symptoms induced by antidepressants in the elderly.
García-Parajuá P; de Ugarte L; Baca E
J Clin Psychopharmacol; 2004 Feb; 24(1):111-2. PubMed ID: 14709967
[No Abstract] [Full Text] [Related]
2. CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.
Vandel P; Bonin B; Vandel S; Sechter D; Bizouard P
Med Hypotheses; 1996 Dec; 47(6):439-42. PubMed ID: 8961239
[TBL] [Abstract][Full Text] [Related]
3. Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly.
Govoni S; Racchi M; Masoero E; Zamboni M; Ferini-Strambi L
Mol Psychiatry; 2001 Mar; 6(2):134-42. PubMed ID: 11317214
[TBL] [Abstract][Full Text] [Related]
4. [Central motor and extrapyramidal side effects under therapy with antidepressants (author's transl)].
Böning J
Fortschr Neurol Psychiatr; 1982 Feb; 50(2):35-47. PubMed ID: 7095714
[No Abstract] [Full Text] [Related]
5. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
6. Do some antidepressants decrease effect of tamoxifen?
J Support Oncol; 2009; 7(4):147-8. PubMed ID: 19731582
[No Abstract] [Full Text] [Related]
7. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
8. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
[TBL] [Abstract][Full Text] [Related]
9. Doxepin inhibits CYP2D6 activity in vivo.
Szewczuk-Bogusławska M; Kiejna A; Beszłej JA; Orzechowska-Juzwenko K; Milejski P
Pol J Pharmacol; 2004; 56(4):491-4. PubMed ID: 15520506
[TBL] [Abstract][Full Text] [Related]
10. Antidepressants and tamoxifen: interaction concerns.
Cass-Verco J; Mason C; Wilcken N
Australas Psychiatry; 2013 Oct; 21(5):508-9. PubMed ID: 24085721
[No Abstract] [Full Text] [Related]
11. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
12. Antidepressants and extrapyramidal effects.
Prescrire Int; 2003 Feb; 12(63):17-8. PubMed ID: 12602380
[No Abstract] [Full Text] [Related]
13. Anthocyanins and anthocyanidins are poor inhibitors of CYP2D6.
Dreiseitel A; Schreier P; Oehme A; Locher S; Rogler G; Piberger H; Hajak G; Sand PG
Methods Find Exp Clin Pharmacol; 2009; 31(1):3-9. PubMed ID: 19357792
[TBL] [Abstract][Full Text] [Related]
14. CYP 2D6 polymorphism and antipsychotic therapy.
Plesnicar BK; Dolzan V; Zalar B
Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
[TBL] [Abstract][Full Text] [Related]
16. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
[TBL] [Abstract][Full Text] [Related]
18. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
19. [The influence of clomipramine on CYP2D6 activity].
Szewczuk-Bogusławska M; Kiejna A; Grzesiak M; Beszłej JA; Chlebowska I; Orzechowska-Juzwenko K; Milejski P
Psychiatr Pol; 2007; 41(2):243-9. PubMed ID: 17598433
[TBL] [Abstract][Full Text] [Related]
20. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
